Effective: 07/01/2025 2025.2 Last Revision: 02/20/2025 Last Clinical Review: 01/31/2025

Ovarian Cancer Diagnostic Algorithmic Tests

- Ovarian cancer diagnostic algorithmic tests (i.e., OVA1, Overa, ROMA, and OvaWatch) are considered investigational for all indications, including but not limited to:
 - A. Preoperative evaluation of adnexal masses to triage for malignancy
 - B. Screening for ovarian cancer
 - C. Selecting members for surgery for an adnexal mass
 - D. Evaluation of members with clinical or radiologic evidence of malignancy
 - E. Evaluation of members with nonspecific signs or symptoms suggesting possible malignancy
 - F. Postoperative testing and monitoring to assess surgical outcome and/or to detect recurrent malignant disease following treatment.

REFERENCES

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 3.2024. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

